Plain-English translation of NCT07437157 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is building a registry of people with type 2 diabetes who also have fatty liver disease. Researchers want to collect blood samples, genetic information, and liver imaging scans from about 1,000 patients to understand how these two conditions are connected and what warning signs predict when someone's liver health might get worse.
Many people with type 2 diabetes also develop fatty liver disease, but doctors don't fully understand why or how to predict who will develop serious liver problems. This study hopes to find blood markers and genetic clues that can help doctors identify patients who need closer monitoring and early treatment.
You likely qualify if…
You likely don't qualify if…
If you join, you will have your blood drawn for testing and genetic analysis, and you will receive a special ultrasound scan called a Fibroscan that checks how much fat and scarring is in your liver. The study team will track your health over time to see how your liver and diabetes progress and which patients develop more serious complications.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
Hong Kong
Sponsor
Chinese University of Hong Kong
Enrollment target
~1,000 participants
Started
June 2025
Primary completion
February 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Alice Pik Shan Kong, MD
Chinese University of Hong Kong
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.